stoxline Quote Chart Rank Option Currency Glossary
Bausch Health Companies Inc. (BHC)
8.55  0.1 (1.18%)    04-23 10:31
Open: 8.5
High: 8.59
Volume: 292,924
Pre. Close: 8.45
Low: 8.43
Market Cap: 3,124(M)
Technical analysis
2024-04-23 10:16:26 AM
Short term     
Mid term     
Targets 6-month :  12 1-year :  13.38
Resists First :  10.27 Second :  11.46
Pivot price 9.09
Supports First :  8.35 Second :  6.95
MAs MA(5) :  8.58 MA(20) :  9.39
MA(100) :  8.53 MA(250) :  8.11
MACD MACD :  -0.3 Signal :  -0.2
%K %D K(14,3) :  6.3 D(3) :  7.5
RSI RSI(14): 37.3
52-week High :  11.46 Low :  5.57
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ BHC ] has closed above bottom band by 27.3%. Bollinger Bands are 106.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 17 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 8.81 - 8.85 8.85 - 8.9
Low: 8.3 - 8.35 8.35 - 8.4
Close: 8.35 - 8.44 8.44 - 8.52
Company Description

Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Headline News

Mon, 22 Apr 2024
Closing Bell: Bausch Health Companies Inc down on Monday (BHC) - The Globe and Mail

Sat, 20 Apr 2024
Mackenzie Financial Corp Boosts Holdings in Bausch Health Companies Inc. (NYSE:BHC) - MarketBeat

Thu, 18 Apr 2024
Closing Bell: Bausch Health Companies Inc down on Thursday (BHC) - The Globe and Mail

Thu, 18 Apr 2024
Bausch Health Cos. Inc. stock falls Thursday, underperforms market - MarketWatch

Wed, 17 Apr 2024
Readystate Asset Management LP Makes New Investment in Bausch Health Companies Inc. (NYSE:BHC) - MarketBeat

Wed, 17 Apr 2024
Closing Bell: Bausch Health Companies Inc down on Wednesday (BHC) - The Globe and Mail

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Drug Manufacturers - Specialty & Generic
Shares Out 367 (M)
Shares Float 304 (M)
Held by Insiders 0.9 (%)
Held by Institutions 79.5 (%)
Shares Short 22,500 (K)
Shares Short P.Month 24,640 (K)
Stock Financials
EPS -1.63
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -2.8
Profit Margin -6.8 %
Operating Margin 21 %
Return on Assets (ttm) 3.8 %
Return on Equity (ttm) -686.6 %
Qtrly Rev. Growth 9.8 %
Gross Profit (p.s.) 0
Sales Per Share 23.89
EBITDA (p.s.) 7.85
Qtrly Earnings Growth 0 %
Operating Cash Flow 1,030 (M)
Levered Free Cash Flow 738 (M)
Stock Valuations
PE Ratio -5.27
PEG Ratio 0.8
Price to Book value -3.05
Price to Sales 0.35
Price to Cash Flow 3.03
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android